Abstract
Mucolytics with efficacy approved for cystic fibrosis (CF) have been reviewed by the authors. Currently, investigators search for new mucoactive agents to improve sputum rheology and expectoration in CF. One the promising mucolytics is inhaled dry powder mannitol which was effective and safe in several international trials. Inhaled mannitol has been implemented in clinical practice for CF treatment in some countries. Therefore, goals of new studies should be optimization the use, determination the target population and investigation of combined therapy with different mucolytics in CF.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
